MarketCap
Facebook
X
Telegram
Tenax Therapeutics Net Income | TENX
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Tenax Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 1967 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -52.6 M | -17.6 M | -7.7 M | 11 M | -32.5 M | 9.85 M | -8.39 M | -6.81 M | -8.84 M | -43.9 M | -14.1 M | -19.5 M | -9.42 M | -15.7 M | -10.4 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 11 M | -52.6 M | -15.1 M |
Quarterly Net Income Tenax Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -17.8 M | -15.7 M | -15.8 M | -10.8 M | -10.4 M | - | -3.96 M | -3.58 M | -3.8 M | - | 1.97 M | -1.11 M | -1.41 M | - | 2.92 M | -2.86 M | -2.72 M | - | 3.8 M | -1.72 M | -23.7 M | - | -2.22 M | -2.15 M | -2.65 M | - | 2.22 M | 1.76 M | 1.62 M | - | 1.54 M | 1.87 M | 1.19 M | - | 1.23 M | 2.99 M | 3.28 M | - | 4.27 M | 4.64 M | -5.36 M | -2.87 M | -2.92 M | -3.52 M | -3.03 M | -3.35 M | -4.05 M | -4.05 M | -2.17 M | -2.41 M | -3.53 M | -3.53 M | -2.25 M | -7.3 M | -1.56 M | -1.56 M | -3.59 M | 2.54 M | -2.93 M | 2.93 M | 2.87 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.64 M | -23.7 M | -2.67 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
1.82 B | $ 263.04 | 0.49 % | $ 465 B |  USA |
 |
AbCellera Biologics
ABCL
|
-146 M | $ 11.41 | 2.15 % | $ 3.41 B |  Canada |
 |
Фармсинтез
LIFE
|
-525 M | - | - | - |  Russia |
 |
Aclaris Therapeutics
ACRS
|
-64.9 M | $ 5.53 | 6.02 % | $ 678 M | USA |
 |
ADC Therapeutics SA
ADCT
|
-143 M | $ 1.09 | 3.74 % | $ 139 M |  Schweiz |
 |
Amryt Pharma plc
AMYT
|
1 M | - | - | $ 621 M |  Britain |
 |
Evelo Biosciences
EVLO
|
-115 M | - | -14.46 % | $ 27.9 M | USA |
 |
Allakos
ALLK
|
-116 M | - | - | $ 28.6 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-61.4 M | - | - | $ 231 M | USA |
 |
Clovis Oncology
CLVS
|
-64.4 M | - | -7.23 % | $ 13 M | USA |
 |
Chimerix
CMRX
|
-88.4 M | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
-80.1 M | - | - | $ 401 M | USA |
 |
ADMA Biologics
ADMA
|
147 M | $ 8.61 | 0.16 % | $ 2.05 B | USA |
 |
Eiger BioPharmaceuticals
EIGR
|
-75 M | - | -9.21 % | $ 2.55 M | USA |
|
89bio
ETNB
|
-367 M | - | - | $ 1.55 B | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-89 M | - | - | $ 384 M | Britain |
 |
Fusion Pharmaceuticals
FUSN
|
-94.9 M | - | - | $ 1.41 B | Canada |
 |
Guardion Health Sciences
GHSI
|
158 K | - | -0.31 % | $ 3.64 M | USA |
 |
Genocea Biosciences
GNCA
|
-33.2 M | - | -15.0 % | $ 3.04 M | USA |
 |
Gritstone Oncology
GRTS
|
-138 M | - | 0.42 % | $ 213 M | USA |
 |
G1 Therapeutics
GTHX
|
-48 M | - | - | $ 370 M | USA |
 |
Harpoon Therapeutics
HARP
|
-67.7 M | - | - | $ 763 M | USA |
 |
Humanigen
HGEN
|
-70.7 M | - | -81.12 % | $ 4.28 M | USA |
 |
HOOKIPA Pharma
HOOK
|
-43.5 M | - | -6.92 % | $ 79.4 M | USA |
 |
Intercept Pharmaceuticals
ICPT
|
-20.8 M | - | - | $ 643 M | USA |
 |
IGM Biosciences
IGMS
|
-196 M | - | - | $ 76.9 M | USA |
 |
IMV
IMV
|
-38 M | - | - | $ 13.1 M | Canada |
 |
Intra-Cellular Therapies
ITCI
|
-16.9 M | - | - | $ 13.6 B | USA |
 |
Kinnate Biopharma
KNTE
|
-113 M | - | - | $ 123 M | USA |
 |
Chinook Therapeutics
KDNY
|
-188 M | - | - | $ 2.6 B | USA |
 |
Kaleido Biosciences
KLDO
|
-90.3 M | - | -3.69 % | $ 12.4 M | USA |
 |
Kronos Bio
KRON
|
-86.1 M | - | 1.49 % | $ 50.8 M | USA |
 |
Karuna Therapeutics
KRTX
|
-434 M | - | - | $ 12.2 B | USA |
 |
Landos Biopharma
LABP
|
-21.9 M | - | 0.58 % | $ 144 M | USA |
 |
La Jolla Pharmaceutical Company
LJPC
|
19.7 M | - | - | $ 154 M | USA |
 |
LogicBio Therapeutics
LOGC
|
-40 M | - | - | $ 229 M | USA |
 |
Lumos Pharma
LUMO
|
-34 M | - | - | $ 35.3 M | USA |
 |
Merrimack Pharmaceuticals
MACK
|
-1.18 M | - | - | $ 216 M | USA |
 |
Stealth BioTherapeutics Corp
MITO
|
-52.5 M | - | - | $ 23.9 M | USA |
 |
Mirati Therapeutics
MRTX
|
-741 M | - | - | $ 3.3 B | USA |
 |
NexImmune
NEXI
|
-32.3 M | - | 70.13 % | $ 4.12 M | USA |
 |
9 Meters Biopharma
NMTR
|
-43.8 M | - | -42.97 % | $ 1.05 M | USA |
 |
InVivo Therapeutics Holdings Corp.
NVIV
|
-10.5 M | - | -37.48 % | $ 476 K | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
-4.49 M | - | -19.68 % | $ 18.4 M | Canada |
 |
ObsEva SA
OBSV
|
-58.4 M | - | -15.52 % | $ 10.5 M | Schweiz |
 |
Oncorus
ONCR
|
-77.4 M | - | -8.54 % | $ 3.19 M | USA |
 |
OncoSec Medical Incorporated
ONCS
|
-34.2 M | - | 31.87 % | $ 1.61 M | USA |
 |
Oncternal Therapeutics
ONCT
|
-39.5 M | - | -24.12 % | $ 1.56 M | USA |
 |
Opiant Pharmaceuticals
OPNT
|
3.01 M | - | - | $ 109 M | USA |
 |
Orchard Therapeutics plc
ORTX
|
-151 M | - | 1.02 % | $ 90.8 M | Britain |